ImmunityBio Investors Have Chance to Lead Class Action Lawsuit Following Major Stock Losses

Investor Alert: ImmunityBio Class Action Lawsuit

Investors who acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 24, 2026, are being urged to step forward as lead plaintiffs in a class action lawsuit against the company. This opportunity arises after substantial stock losses attributed to misleading statements made by the company’s executives, particularly concerning its lead product, Anktiva.

Background on ImmunityBio

ImmunityBio is a biotechnology firm focused on developing innovative immunotherapies. The company's positioning centers around its flagship product, Anktiva, which it claims can revolutionize treatment protocols for certain cancers. However, claims regarding Anktiva's effectiveness and its categorization as a cancer vaccine have faced scrutiny.

Allegations of Misleading Statements

The class action lawsuit alleges that ImmunityBio and its Executive Chairman, Dr. Patrick Soon-Shiong, made several false statements about Anktiva's capabilities. Notably, they claimed that all NMIBC patients treated with Anktiva would be cancer-free long-term, a statement that has not been substantiated. The lawsuit asserts that these misrepresentations contributed to inflated stock prices, and once the truth came to light, the company's share price plummeted.

The FDA Warning Letter

On March 24, 2026, a letter from the U.S. Food and Drug Administration (FDA) surfaced, indicating that ImmunityBio misbranded Anktiva in promotional materials, violating the Federal Food, Drug, and Cosmetic Act. The FDA highlighted public health concerns over the misleading implications that Anktiva could cure all forms of cancer. Following this announcement, ImmunityBio’s stock experienced a dramatic 21% decline, leading to substantial financial losses for investors.

The Role of Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows investors who incurred losses during the defined Class Period to apply for lead plaintiff status. The lead plaintiff acts on behalf of all affected investors, directing the lawsuit and collaborating with legal representation of their choosing. Notably, participation as a lead plaintiff does not affect an investor’s eligibility for a recovery in any eventual settlement.

Legal Representation and Contact Information

Robbins Geller Rudman & Dowd LLP is spearheading the class action and encourages interested investors to claim their lead plaintiff rights by May 26, 2026. Investors can reach out to attorneys Ken Dolitsky or Michael Albert by calling 800-449-4900 or via email at [email protected].

Conclusion

This class action could serve as a crucial means of recourse for those affected by ImmunityBio’s alleged corporate misdoings. If you've experienced substantial losses and wish to join the lawsuit, taking action soon is essential. For inquiries or further details about the lawsuit process, please contact the legal team linked within this article.